/06 Jun 2017/By Alpana Prasad, PhD Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells Class I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen but also through Fc domain-mediated recruitment... Read More